Kristin Stephens - Syros Pharmaceuticals Chief Officer

Syros Pharmaceuticals Management Efficiency

The company has return on total asset (ROA) of (0.5988) % which means that it has lost $0.5988 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (7.7696) %, meaning that it created substantial loss on money invested by shareholders. Syros Pharmaceuticals' management efficiency ratios could be used to measure how well Syros Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.03 in 2024. Return On Capital Employed is likely to drop to -1.03 in 2024. At this time, Syros Pharmaceuticals' Net Tangible Assets are comparatively stable compared to the past year. Debt To Assets is likely to gain to 0.27 in 2024, whereas Total Assets are likely to drop slightly above 147.5 M in 2024.

Similar Executives

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts. Syros Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 124 people. Syros Pharmaceuticals (SYRS) is traded on NASDAQ Exchange in USA. It is located in 35 CambridgePark Drive, Cambridge, MA, United States, 02140 and employs 68 people. Syros Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Syros Pharmaceuticals Leadership Team

Syros Stock Performance Indicators

Additional Tools for Syros Stock Analysis